Quantcast
Channel: Texas Headlines on One News Page
Viewing all 55103 articles
Browse latest View live

Monster Energy’s Kyle Baldock Takes Gold in Dave Mirra’s BMX Best Trick and Snags Bronze in BMX Park at X Games Austin 2016

0
0
Monster Energy congratulates Kyle Baldock on his bronze medal in BMX Park and Gold in the first-ever Dave Mirra Best Trick contest.

Austin, Texas (PRWEB) June 05, 2016

Monster Energy congratulates Kyle Baldock on his bronze medal in BMX Park and Gold in the first-ever Dave Mirra Best Trick contest. Day 3 of X Games Austin 2016 saw Baldock take to the park course like a man possessed. And perhaps he was, considering he was one of the last guys to session with former Monster Energy Ambassador and BMX legend Dave Mirra who tragically passed in February.

Undoubtedly, one of the most powerful moments of X Games Austin unfolded today as the Dave Mirra Best Trick Contest went down. Mirra was a pioneer in freestyle BMX and one of the primary reasons it is the sport it is today. Simply put, his impact was profound to say the least. That said, today’s best riders showed up to pay their respects to the legend for the Best Trick contest which now bears Mirra’s name.

“He was like a father figure,” Baldock said of Mira, “I don’t think I would be who I am today without him.”

With that, Kyle gave a packed crowd a moment to remember blasting a massive 720 double tail whip off the parks biggest feature en route to the victory.

As fans lost it in disbelief the judges were left stunned having no choice but to award the Golden Pedal award to the kid from the Gold Coast of Australia.

This came just minutes after taking Bronze in the BMX Park contest where after a fall on his initial run Baldock dropped in to his final run like a man on fire effortlessly chucking flairs in both directions, a corked 720 and a stunning double back flip mid run.

“I truly did it for Dave, said Baldock. I saw his kids in the crowd and just went for it with the double backy.”

The feat secured his only X Games Bronze (his other 5 medals are all Gold).

Despite his accomplishments Baldock acknowledged that today was not about him stating, “All I want to do is give back the same love and respect to our sport that my friend Dave did.”

For more visit http://www.monsterenergy.com and Monster Energy Facebook this week to score all the exclusive updates from X Games Austin 2016 including photos, videos, and contest results as they happen. Follow us on Instagram and Twitter and search #UnleashedAtX for exclusive behind-the-scenes looks in Austin.

###

About Monster Energy
Based in Corona, California, Monster Energy is the leading marketer and distributor of energy drinks and alternative beverages. Refusing to acknowledge the traditional, Monster Energy supports the scene and sport. Whether motocross, off-road, NASCAR, MMA, BMX, surf, snowboard, ski, skateboard, or the rock and roll lifestyle, Monster Energy is a brand that believes in authenticity and the core of what its sports, athletes and musicians represent. More than a drink, it’s the way of life lived by athletes, sports, bands, believers and fans. See more about Monster Energy including all of its drinks at http://www.monsterenergy.com. Reported by PRWeb 11 hours ago.

Kryptek Announces Final Judgment In Copyright, Patent, And Trademark Infringement Case Against Salt Armour, Inc.

0
0
Kryptek Outdoor Group, LLC, today announced that the United States District Court for the Eastern District of Texas has rendered a Final Judgment and Permanent Injunction against Defendants Salt Armour, Inc., Alpha Defense, Inc. and Thomas J. DeSernia for infringement of Kryptek’s intellectual property.

BEAUMONT, TX (PRWEB) June 05, 2016

Kryptek Outdoor Group, LLC, a cutting-edge camouflage and apparel solutions company founded by U.S. Army veterans, today announced that the United States District Court for the Eastern District of Texas has rendered a Final Judgment and Permanent Injunction against Defendants Salt Armour, Inc., Alpha Defense, Inc. and Thomas J. DeSernia for infringement of Kryptek’s intellectual property, resolving a lawsuit filed by Kryptek on September 9, 2015.

Kryptek filed the lawsuit after Defendants ignored Kryptek’s multiple requests to cease and desist creating, offering for sale, and selling counterfeit copies of Kryptek’s camouflage patterns and products on multiple websites that Defendant’s owned and operated. Kryptek developed and released its innovative patterns and products in connection with the U.S. Army Camouflage Improvement Effort begun in 2011. Defendants further falsely claimed that the counterfeited patterns were their exclusive creations and tried to conceal their true origin by renaming them.        

According to the Final Judgment and Permanent Injunction of March 29, 2016, the Court found that Defendants had infringed on Kryptek’s copyrighted and patented camouflage patterns and willfully infringed on Kryptek’s trademarks, and ordered Defendants to pay One Million, Seventy-Five Thousand Dollars ($1,075,000.00) as damages for the infringement, plus attorneys’ fees and costs of court. The Court also permanently enjoined Defendants from further infringing activities.

Butch Whiting, CEO/Co-founder of Kryptek stated after the Final Judgment was entered by the Court: “We are pleased that the Court put a stop to this and is holding the Defendants accountable for their actions. We also hope this judgment sends a clear signal of our intentions to vigorously defend against further theft of our creations moving forward, both domestically and abroad.”

The case is Kryptek Outdoor Group, LLC v. Salt Armour, Inc., Alpha Defense, Inc., and Thomas J. De Sernia, case number 1:15-cv-00348-RC, in the United States District Court for the Eastern District of Texas, Beaumont Division. Kryptek is represented by Stewart Mesher and Darlene Ghavimi of Conley Rose P.C. Reported by PRWeb 11 hours ago.

Sports › Odor back from ban to help Rangers beat Mariners 10-4

0
0
Texas' Rougned Odor scored twice in his return from a seven-game suspension, helping the Rangers beat Seattle 10-4 on Saturday to open a two-game lead on the Mariners atop the American League West standings. Odor was banned for punching Toronto's Jose Bautista in a hangover from a feud that erupted… Reported by Japan Today 10 hours ago.

Odor back from ban to help Rangers beat Mariners 10-4

0
0
ARLINGTON, Texas (AP) " Texas' Rougned Odor scored twice in his return from a seven-game suspension, helping the Rangers beat Seattle 10-4 on Saturday to open a two-game lead on the Mariners atop the American League West standings.Odor... Reported by New Zealand Herald 11 hours ago.

US: Louisiana, Mississippi areas under flood watch as Texas floods spread

0
0
Heavy rains are expected to strike the states of Louisiana and Mississippi, but not as intensely as Texas, where rivers have swelled to levels not seen in more than 100 years Reported by DNA 10 hours ago.

Sharleen Spiteri spent her Top Gear time 'effing and blinding in Scottish' during her terrifying race in Africa

0
0
Sharleen Spiteri spent her Top Gear time 'effing and blinding in Scottish' during her terrifying race in Africa THE Texas singer described her adventure as the ultimate road trip, admitting she went a few days without showering in her cross country car race. Reported by Daily Record 10 hours ago.

Fort Hood releases names of soldiers killed in training accident

0
0
Fort Hood officials released the names of eight of the nine soldiers Saturday who were killed earlier this week in Texas after floodwaters overturned an Army tactical vehicle at a low-water crossing during a training exercise. Reported by FOXNews.com 9 hours ago.

Comparing Cost Of Living Abroad: Apples To Apples

0
0
Apples to apples.

That's the principle to keep in mind when comparing costs, both for living and for buying real estate overseas.

Readers of my daily e-letter, Overseas Opportunity Letter, write in to take issue with our costs references every day.

"Restaurants in Panama are 35 percent more expensive than restaurants in the United States," wrote one reader recently, after having visited Panama.

Another wrote last week to tell me he could buy an apartment in Nashville for half the price of an apartment on Ambergris Caye.

A third got in touch to explain how the United States is, in fact, a less expensive place to live than Mexico.

All of these assertions are commonly flawed. They aren't comparing apples to apples. Frankly, it's hard to say what they are comparing.

Every restaurant in every city and town in Panama is 35 percent more expensive than every restaurant in every city and town in the United States?

That can't be what the reader meant...

I don't doubt that you could buy an apartment in Nashville (or in many other cities across the United States) for the same cost per square foot or less than you'd spend for an apartment on Ambergris Caye.

Of course, Ambergris is a Caribbean island boasting long white-sand beaches and the best snorkeling and diving in the world. An apartment in Nashville doesn't seem to compare, does it?

Or maybe it does. It depends on what's important to you.

If you want to live near the ocean, you're going to spend more per square foot for your place of residence than you would for an apartment in any random land-locked city.

If living near the ocean isn't important to you, then you don't have to concern yourself with beachfront pricing.

One couple recently visited Panama, stopped in a couple of grocery stores, and checked prices at the pumps. Their conclusion? Food and gas prices in this country are "much higher than back home."

Maybe some specific grocery items are more expensive than the same foods in this couple's home town. But, again, you've got to compare apples to apples. Processed foods imported from the States are going to cost more anywhere. If you want them, you're going to have to pay the price.

However, shop not at the U.S.-style grocery stores but at the local markets, and your apples, tomatoes, lettuce, onions, peppers, corn, rice, and locally raised beef and chicken will cost you less than they do back home. I'd bet on it.

Is the price of gas higher in Panama than in the States? Depends where in the States you're comparing to and what kind of gas you're buying. We could compare figures for a gallon of 91 octane in Panama City with those for a gallon of 91 octane in Dallas, Texas, Baltimore, Maryland, or San Diego, California.

But, frankly, that seems a bit tedious. And it misses the point.

Are you going to base your retire-overseas decision on the cost of a gallon of 91 octane gasoline?

I hope not.

Depending where you're moving from and where you decide to move to, some things are going to cost less (maybe dramatically less), and some things are going to cost more. You've got to consider overall costs of living and not be distracted by the cost of a loaf of bread.

In other words, compare not only apples to apples, but baskets of costs to comparable baskets of costs.

Back home you're likely paying hefty annual property taxes ... maybe US$10,000 per year or more depending on state of residence. In many countries, you won't have to pay property taxes at all. In others that impose property taxes (including France, Colombia, and Belize, for example), they're negligible.

Back home you likely don't have a maid or a gardener. If you do, the help is likely part-time and expensive. In some parts of Central America, you could have full-time help around the house for as little as US$150 a month.

If your only goal in retirement is to live cheap, you could probably save yourself the trouble of relocating to another country and seek out, instead, a super-low-cost locale Stateside. Living a modest lifestyle in a small town in Alabama or Iowa, for example, you could maybe do OK on your Social Security income.

However, you can't compare modest, small-town life in middle America with beachfront living on a Caribbean island ... a new life in a centuries-old Colonial city ... an expansive view of the crashing Pacific from your balcony ... or discovering the charms and historic traditions of country life on the Continent...

This isn't only about the money.

Keep in mind how much more affordable your life could be living in certain places overseas. This isn't hype. It's fact.

It's also relative. The particulars depend on where you're coming from, where you're moving to, and how you intend to live.

I hope, though, that we do as good a job helping you recognize the other benefits of investing in a new life in a new country.

I can't tell you where you should go (though I'm happy to continue to make suggestions). I can't tell you how much more affordable your life is going to be once you get there (one more time, this will depend on where and how you want to live).

But I can tell you that boiling this adventure down to a line-item comparison of costs for things like cable television and a pound of ground beef is a mistake. And basing your decision to move (or not) on that kind of thinking is doing yourself a disservice.

It won't always be easy, but you've got to keep the big picture in mind.

Moving to another country, at any point in your life, would be the adventure of your lifetime.

Start with that. And stay the course.

*Related Articles*:

The Cost Of Living In Nicaragua: A Top Retirement And Vacation Hotspot

Living In Europe On A Budget Just Got Easier

Corozal On A Budget--How This Single Pensioner Moved To Belize And Began Her New Affordable Life In ParadiseEarlier on Huff/Post50:-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 6 hours ago.

ASCO 2016: Phase I study protocol investigating IPH4102 in cutaneous T-Cell lymphomas

0
0
· * Phase I study of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas commenced in November 2015 and continues on track in EU and US centers *

*Marseille, France, June 5, 2016*

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris discussed the protocol of the ongoing first in human study of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas (CTCL) in a "Trial in progress" poster at the 2016 ASCO ^[1] annual meeting (June 3-7, 2016, in Chicago, USA).

The poster has been made available on the Company's website, in the Product Pipeline - IPH4102 section.

* About IPH4102 Phase I trial: *

The Phase I trial is an open label, multicenter study of IPH4102 in patients with relapsed/refractory CTCL which is performed in Europe (France, Netherlands, United Kingdom) and in the US. Participating institutions include several hospitals with internationally recognized expertise: the Saint-Louis Hospital (Paris, France), the Stanford University Medical Center (Stanford, CA), the Ohio State University (Columbus, OH), the MD Anderson Cancer Center (Houston, Texas), the Leiden University Medical Center (Netherlands), and the Guy's and St Thomas' Hospital (United Kingdom). Approximately 60 patients with KIR3DL2-positive CTCL having received at least two prior lines of systemic therapy are expected to be enrolled in two sequential study parts:

       -      A dose-escalation part including approximately 40 CTCL patients in 10 dose levels. Its objective is to identify the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D); the dose-escalation follows an accelerated 3+3 design;

       -      A cohort expansion part with 2 cohorts of 10 patients each in 2 CTCL subtypes (transformed mycosis fungoides and Sézary syndrome) receiving IPH4102 at the RP2D until progression. Cohort design (CTCL subtype, number of patients.) may be revisited based on the findings in the dose escalation part of the study.

The primary objective of this trial is to evaluate the safety and tolerability of repeated administrations of single agent IPH4102 in this patient population. The secondary objectives include assessment of the drug's antitumor activity. A large set of exploratory analyses aims at identifying biomarkers of clinical activity. Clinical endpoints include overall objective response rate, response duration and progression-free survival.

This trial is expected to deliver data for the dose escalation and cohort expansion at the end of 2017 and 2018 respectively.

* About IPH4102: *

IPH4102 is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed to trigger killing of cutaneous T-cell lymphomas ("CTCL") cancer cells, an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, specifically expressed on all subtypes of CTCL and has a restricted expression on normal tissues. Potent antitumor properties of IPH4102 were shown against human CTCL cells in vitro and in vivo in a mouse model of KIR3DL2+ tumors, in which IPH4102 reduced tumor growth and improved survival. The efficacy of IPH4102 was further evaluated in laboratory assays using the patients' own natural killer (NK) cells against their primary tumor samples in the presence of IPH4102. These studies were performed in patients with Sézary Syndrome; Sézary Syndrome is the leukemic form of CTCL and is known to have a very poor prognosis. In these experiments, IPH4102 selectively and efficiently induced killing of the patients' CTCL cells. These results were published in Cancer Research in 2014 ( http://www.ncbi.nlm.nih.gov/pubmed/25361998 ).

IPH4102 was granted orphan drug status in the European Union for the treatment of CTCL.

*About Innate Pharma:*

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells.

The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms.

Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.

Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com .

*Practical Information about Innate Pharma shares:*

*ISIN code*
*Ticker code* FR0010331421
IPH*
*

*Disclaimer:*

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( http://www.amf-france.org ) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

*For additional information, please contact:*

*Innate Pharma* *Press Contacts*
Laure-Hélène Mercier
Director, Investor Relations *ATCG Press (France)*
Marie Puvieux
Tel.: +33 (0)4 30 30 30 87 Mob: +33 (0)6 10 54 36 72
investors@innate-pharma.com presse@atcg-partners.com

* * *Consilium Strategic Communications (ROW)*
  Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Hendrik Thys
  Tel.: +44 (0)20 3709 5700
  InnatePharma@consilium-comms.com --------------------

^[1] American Society of Clinical Oncology

asco 2016: Phase I study protocol investigating IPH4102 in CTCL
--------------------This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INNATE PHARMA via GlobeNewswire

HUG#2018058 Reported by GlobeNewswire 5 hours ago.

Husky asset sales point to uneven growth in energy mergers, acquisitions

0
0
*By The Canadian Press*

CALGARY — A two-tier marketplace is developing for western Canadian oil and gas properties, with bidders starting to line up to buy crude-producing properties — although companies marketing natural gas wells are finding few takers.

Volatility in oil and gas prices over the past year have scared many buyers out of the market while making valuations difficult for buyers and sellers to agree upon, observers say.

Benchmark West Texas Intermediate oil rose above US$50 per barrel... // Read Full Article Reported by CJME 3 hours ago.

Fort Worth grandmother among more than 100 North Texas soldiers deploying to Middle East

0
0
Reported by DallasNews 4 hours ago.

Pastor Shot in Head While at Beauty Salon Window Recalls 'It Was So Surreal'

0
0
A church pastor from Texas was hit by a gunshot at a beauty salon in her home town Minneapolis after an unidentified man suddenly fired multiple shots. The bullet grazed the back of her head and nicked an artery. Reported by Christian Post 3 hours ago.

Pet-sitting company sues couple for $1 million over bad review

0
0
Fish — one of nature's most fragile, and litigious, pets.

When Michelle and Robert Duchouquette, of Plano, Texas went away on vacation last year, the couple left their two dogs and Betta fish, Gordy, in the hands of Prestigious Pets. After returning from their vacation, the couple noticed that Gordy's bowl was cloudy — a consequence of overfeeding. So the Duchouquettes posted a negative review on Yelp — and Prestigious Pets countered with a friendly $1 million lawsuit.

SEE ALSO: Bald eagle steals catch right from Canadian fisherman's line

Seems entirely reasonable.

The company claims that the couple had signed a contract agreeing "not to make negative comments about Prestigious Pets and to not disparage Prestigious Pets." According to the lawsuit, the Duchouquette's allegations went beyond a simple one star Yelp review and included a variety of written and broadcast mediums, including Facebook, ABC, and NBC. Read more...

More about Lawsuits, Fish, Weird News, Wtf, and Watercooler Reported by Mashable 3 hours ago.

N.J. solider identified as victim in Fort Hood training accident

0
0
A Jersey City native has been identified as one of nine soldiers killed during a training accident at a Texas army base, officials announced. Reported by NJ.com 3 hours ago.

Rains slow, but flooding still threatens part of Texas

0
0
It's been several days since deadly flooding began in parts of southeast and central Texas, and the rain just started to let up Saturday. Reported by FOXNews.com 19 minutes ago.

Immunotherapy Effective Against Some Types of Sarcoma

0
0
An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute. Additional analyses of tumor biopsies and blood samples, which will help the researchers better understand which sarcoma subtypes will benefit most from the new treatment, are underway.

Pittsburgh, PA (PRWEB) June 05, 2016

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of tumor biopsies and blood samples, which will help the researchers better understand which sarcoma subtypes will benefit most from the new treatment, are underway.

Interim results from the phase II clinical trial were presented today at the 52nd annual American Society of Clinical Oncology (ASCO) annual meeting in Chicago by principal investigator Hussein Abdul-Hassan Tawbi, M.D., Ph.D., formerly of UPCI and current associate professor, University of Texas MD Anderson Cancer Center.

Sarcoma is a rare disease, encompassing less than 1 percent of adult cancers, and the available treatments are limited, so the need for new therapies is high, explained the current lead investigator for the Pittsburgh site, Melissa Burgess, M.D., assistant professor of medicine at UPCI.

“This is a pivotal trial for sarcoma, the first and largest trial to be conducted using this specific immunotherapeutic approach. What makes this trial special is that we collected biopsies and blood samples to really study how the treatment is working or not working in these patients. These immune monitoring studies will offer unique insights into the biology of immunotherapy in sarcoma,” Dr. Burgess said.

Immunotherapies work by using a patient’s own immune cells to target cancer cells. The new trial examined the safety and effect of pembrolizumab, which currently is approved for use in advanced melanoma and certain types of advanced lung cancer, on tumor size in four types of soft tissue sarcomas and three types of bone sarcomas.

UPCI, the first of 12 sites to enroll subjects, contributed approximately one quarter of the 80 total patients. Patients received the drug every three weeks. Tumor assessments began at eight weeks and were conducted every 12 weeks thereafter. The trial enrolled on a rolling basis, and is still in progress, so in these results, not all patients have received the drug for the same amount of time.

About 20 percent of patients in the combined soft tissue sarcoma group showed a reduction in tumor size during at least one time point. However, when the researchers looked at the sarcoma subtypes individually, they found one with especially promising results: 44 percent of patients with undifferentiated pleomorphic sarcoma experienced a reduction in tumor size. Encouraging improvements in tumor size also were found in two subtypes of bone sarcomas, osteosarcoma and chondrosarcoma, Dr. Burgess noted.

“Unfortunately, these early results suggest that there is limited efficacy of pembrolizumab in the patient population as a whole. However, it’s promising that the drug seems to be beneficial in specific sarcoma subtypes. Our ongoing immune monitoring studies will allow us to better characterize the patients who will most benefit from this therapy for future clinical trials,” said Dr. Burgess.

Funding for the trial was provided by Merck & Co., the maker of pembrolizumab, Sarcoma Alliance for Research Through Collaboration, Sarcoma Foundation of America and QuadW Foundation. Funding for the ongoing studies was partially provided by local philanthropic support group Pittsburgh Cure Sarcoma. Reported by PRWeb 2 hours ago.

Pregame: Mariners ace Felix Hernandez slowly progressing from calf injury, could miss two more starts

0
0
Pregame notes, matchups, lineups, injury updates and other tidbits before Sunday's game vs. the Texas Rangers at Globe Life Park. Reported by Seattle Times 12 minutes ago.

Leviathan partners refute government claim of smaller gas reserve

0
0
Leviathan partners refute government claim of smaller gas reserve Texas-based Noble Energy Delek Group subsidiaries Delek Drilling and Avner Oil Exploration (each with 22.6 percent) and Ratio Oil Exploration (15%) refuted the Ministry's latest estimate. Reported by Jerusalem Post 6 minutes ago.

Supreme Court to reconsider death penalty in two Texas cases

0
0
The Supreme Court said Monday it will reconsider two Texas death penalty cases in a sign that liberal justices may try to rein in the use of capital punishment.

In one case, a man convicted of a 1980 shooting during a store robbery in Houston says he suffers from a mild mental disability. The justices... Reported by L.A. Times 1 hour ago.

Congressman To Donald Trump: Shove The Border Wall 'Up Your Ass'

0
0
WASHINGTON - U.S. Rep. Filemon Vela took a poison pen to the Republican presumptive presidential nominee, Donald Trump, in an open letter Monday morning. 

"Mr. Trump, you’re a racist and you can take your border wall and shove it up your ass," the Brownsville Democrat wrote in a lengthy missive to the real estate magnate. Vela notes in the letter that he agreed with Trump on some policies, like improving veterans care, addressing Mexican drug cartels and deporting criminal felons who are in the country illegally. But then he savages Trump for his rhetoric on those of Mexican descent and his promise to build a wall on the southern U.S. border. 

"While you would build more and bigger walls on the U.S.-Mexico border, I would tear the existing wall to pieces," Vela wrote. "Why any modern-thinking person would ever believe that building a wall along the border of a neighboring country, which is both our ally and one of our largest trading partners, is frankly astounding and asinine." 

Vela then defended U.S. District Court Judge Gonzalo Curiel, the judge overseeing litigation related to Trump's education enterprise, Trump University, with fraud. Trump has questioned Curiel's capacity for fairness based on his Mexican heritage. Curiel was born in Indiana. 
Vela then pointed out that his own family lineage in the United States goes back farther than Trump's paternal grandfather. 

"Before you dismiss me as just another 'Mexican,' let me point out that my great-great grandfather came to this country in 1857, well before your own grandfather," he wrote. "His grandchildren (my grandfather and his brothers) all served our country in World War I and World War II. His great-grandson, my father, served in the U.S. Army and, coincidentally, was one of the first 'Mexican' federal judges ever appointed to the federal bench." 

"I will not presume to speak on behalf of every American of Mexican descent, for every undocumented worker born in Mexico who is contributing to our country every day or, for that matter, every decent citizen in Mexico," he added. 

U.S. Rep. Filemon Vela, D-Brownsville, is speaking at the 2016 Texas Tribune Festival. Find out more at texastribune.org/festivalThis article originally appeared in The Texas Tribune.

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 2 hours ago.
Viewing all 55103 articles
Browse latest View live




Latest Images